Dr. Elizabeth Winzeler Elected to National Academy of Medicine
Elizabeth Winzeler was recognized by her peers with one of the highest honors in health and medicine. Read more.
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials
Malaria parasites are evolutionarily prepared to resist drug attack. Resistance is emerging to even the latest frontline combination therapies, which target the blood stages of the Plasmodium parasite. Full text Reprint
An improbable journey: Creativity helped me make the transition from art to curing malaria
by Elizabeth Winzeler
Unlike my peers in science, it didn’t occur to me that I might become a scientist (although my immediate family is full of academics and teachers). I didn’t have a microscope as a child and tended to eschew subjects like chemistry. Abstract Read more…
Channel 10 News Features the Winzeler Lab
Jim Patton of Channel 10 News: “It’s a disease that kills nearly a half million people a year. Mostly children. But painstaking work right here in San Diego is bringing the world ever closer to ending malaria.” Read more…
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
Malaria has a disproportionately negative impact on human health because its causal protozoan parasites are adept at changing their genomes to evade antimalarial drugs and the human immune system. Full text Reprint
Researchers Map Druggable Genomic Targets in Evolving Malaria Parasite
Researchers at University of California San Diego School of Medicine, with colleagues across the country and around the world, have used whole genome analyses and chemogenetics to identify new drug targets and resistance genes in 262 parasite cell lines of Plasmodium falciparum — protozoan pathogens that cause malaria — that are resistant to 37 diverse antimalarial compounds. Read more…
Winzeler lab awarded MMV Project of the Year
Dr Winzeler received the award for her contributions to antimalarial drug discovery, which in part led to the identification of KAF156 and Cipargamin as antimalarial compounds, both of which are now in clinical development with Novartis and MMV. Read more…
Evolve and survive
Directed evolution is an experimental strategy that is used to mimic natural selection to generate a library of biomolecule variants. Read more…
Gates Foundation boosts UCSD-led malaria research
The Bill and Melinda Gates Foundation has awarded a $4.7 million supplemental grant to a UC San Diego-led research consortium to develop therapies to eradicate malaria. Read more…
New Grant Boosts UC San Diego-Led Malaria Research Program
An international research team, led by principal investigator Elizabeth A. Winzeler, PhD, professor in the pediatric division of host-microbe systems and therapeutics at University of California San Diego School of Medicine, and colleagues have received a three-year, $4.7 million supplemental grant from the Bill & Melinda Gates Foundation to advance their development of improved therapies for malaria eradication and elimination. Read more…
